{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T15:20:10Z","timestamp":1790436010223,"version":"4.1.0"},"reference-count":77,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,11,18]],"date-time":"2020-11-18T00:00:00Z","timestamp":1605657600000},"content-version":"am","delay-in-days":291,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["W81XWH-18-0257"],"award-info":[{"award-number":["W81XWH-18-0257"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000738","name":"U.S. Department of Veterans Affairs","doi-asserted-by":"publisher","award":["BX003692"],"award-info":[{"award-number":["BX003692"]}],"id":[{"id":"10.13039\/100000738","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Clinics of North America"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1016\/j.ucl.2019.09.006","type":"journal-article","created":{"date-parts":[[2019,11,19]],"date-time":"2019-11-19T12:41:03Z","timestamp":1574167263000},"page":"35-46","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Genomic and Therapeutic Landscape of Non-muscle-invasive Bladder Cancer"],"prefix":"10.1016","volume":"47","author":[{"given":"Lauren Folgosa","family":"Cooley","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly A.","family":"McLaughlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua J.","family":"Meeks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ucl.2019.09.006_bib1","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.ccell.2017.08.015","article-title":"Molecular landscape of non-muscle invasive bladder cancer","volume":"32","author":"Meeks","year":"2017","journal-title":"Cancer Cell"},{"issue":"5","key":"10.1016\/j.ucl.2019.09.006_bib2","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.ccell.2017.08.005","article-title":"Genomic subtypes of non-invasive bladder cancer with distinct metabolic profile, clinical outcome, and female gender bias in KMD2A mutation frequency","volume":"32","author":"Hurst","year":"2017","journal-title":"Cancer Cell"},{"issue":"7492","key":"10.1016\/j.ucl.2019.09.006_bib3","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/nature12965","article-title":"Comprehensive molecular characterization of urothelial bladder carcinoma","volume":"507","year":"2014","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.ucl.2019.09.006_bib4","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.cell.2017.09.007","article-title":"Comprehensive molecular characterization of muscle-invasive bladder cancer","volume":"171","author":"Robertson","year":"2017","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.ucl.2019.09.006_bib5","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1016\/j.celrep.2014.10.035","article-title":"Independent component analysis uncovers the landscape of the bladder tumor transcriptome and reveals insights into luminal and basal subtypes","volume":"9","author":"Biton","year":"2014","journal-title":"Cell Rep"},{"issue":"12","key":"10.1016\/j.ucl.2019.09.006_bib6","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1002\/emmm.201302655","article-title":"An essential role for decorin in bladder cancer invasiveness","volume":"5","author":"El Behi","year":"2013","journal-title":"EMBO Mol Med"},{"issue":"4","key":"10.1016\/j.ucl.2019.09.006_bib7","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/nrurol.2017.11","article-title":"The evolving genomic landscape of urothelial carcinoma","volume":"14","author":"Glaser","year":"2017","journal-title":"Nat Rev Urol"},{"issue":"7457","key":"10.1016\/j.ucl.2019.09.006_bib8","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/nature12213","article-title":"Mutational heterogeneity in cancer and the search for new cancer-associated genes","volume":"499","author":"Lawrence","year":"2013","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.ucl.2019.09.006_bib9","doi-asserted-by":"crossref","first-page":"4537","DOI":"10.18632\/oncotarget.23344","article-title":"APOBEC-mediated mutagenesis in urothelial carcinoma is associated with improved survival, mutations in DNA damage response genes, and immune response","volume":"9","author":"Glaser","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.ucl.2019.09.006_bib10","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ccell.2016.05.004","article-title":"Comprehensive transcriptional analysis of early-stage urothelial carcinoma","volume":"30","author":"Hedegaard","year":"2016","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ucl.2019.09.006_bib11","doi-asserted-by":"crossref","first-page":"5894","DOI":"10.1158\/0008-5472.CAN-16-0436","article-title":"Paired exome analysis reveals clonal evolution and potential therapeutic targets in urothelial carcinoma","volume":"76","author":"Lamy","year":"2016","journal-title":"Cancer Res"},{"key":"10.1016\/j.ucl.2019.09.006_bib12","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1016\/j.celrep.2014.04.038","article-title":"Mutational context and diverse clonal development in early and late bladder cancer","volume":"7","author":"Nordentoft","year":"2014","journal-title":"Cell Rep"},{"key":"10.1016\/j.ucl.2019.09.006_bib13","doi-asserted-by":"crossref","first-page":"5865","DOI":"10.1158\/1078-0432.CCR-12-1807","article-title":"Novel tumor subgroups of urothelial carcinoma of the bladder defined by integrated genomic analysis","volume":"18","author":"Hurst","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ucl.2019.09.006_bib14","doi-asserted-by":"crossref","first-page":"7012","DOI":"10.1158\/1078-0432.CCR-05-0177","article-title":"Bladder cancer stage and outcome by array-based comparative genomic hybridization","volume":"11","author":"Blaveri","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ucl.2019.09.006_bib15","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/0165-4608(84)90100-6","article-title":"Cytogenetic analysis of 62 transitional cell bladder carcinomas","volume":"11","author":"Granberg-Ohman","year":"1984","journal-title":"Cancer Genet Cytogenet"},{"key":"10.1016\/j.ucl.2019.09.006_bib16","first-page":"2860","article-title":"Marked genetic differences between stage pTa and stage pT1 papillary bladder cancer detected by comparative genomic hybridization","volume":"57","author":"Richter","year":"1997","journal-title":"Cancer Res"},{"issue":"18","key":"10.1016\/j.ucl.2019.09.006_bib17","first-page":"30398","article-title":"Mutational landscape of non-muscle-invasive bladder cancer","volume":"S1078-1439","author":"Hurst","year":"2018","journal-title":"Urol Oncol"},{"key":"10.1016\/j.ucl.2019.09.006_bib18","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1038\/nm.3678","article-title":"A\u00a0new tumor suppressor role for the Notch pathway in bladder cancer","volume":"20","author":"Rampias","year":"2014","journal-title":"Nat Med"},{"key":"10.1016\/j.ucl.2019.09.006_bib19","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1186\/1471-2407-14-628","article-title":"Canonical Notch signaling is inactive in urothelial carcinoma","volume":"14","author":"Griefe","year":"2014","journal-title":"BMC Cancer"},{"issue":"2","key":"10.1016\/j.ucl.2019.09.006_bib20","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1172\/JCI78185","article-title":"NOTCH pathway inactivation promotes bladder cancer progression","volume":"125","author":"Maraver","year":"2015","journal-title":"J\u00a0Clin Invest"},{"issue":"6104","key":"10.1016\/j.ucl.2019.09.006_bib21","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1126\/science.1226344","article-title":"Genome sequencing identifies a basis for everolimus sensitivity","volume":"228","author":"Iyer","year":"2012","journal-title":"Science"},{"key":"10.1016\/j.ucl.2019.09.006_bib22","article-title":"Rapamycin prevents surgery-induced immune dysfunction in patients with bladder cancer","author":"Svatek","year":"2018","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.ucl.2019.09.006_bib23","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1016\/S0002-9440(10)64665-2","article-title":"Frequent FGFR3 mutations in papillary non-invasive bladder (pTa) tumors","volume":"158","author":"Billerey","year":"2001","journal-title":"Am J Pathol"},{"key":"10.1016\/j.ucl.2019.09.006_bib24","doi-asserted-by":"crossref","first-page":"2555","DOI":"10.1002\/1097-0142(20011115)92:10<2555::AID-CNCR1607>3.0.CO;2-M","article-title":"The incidence of thanatophoric dysplasia mutations in FGFR3 gene is higher in low-grade or superficial bladder carcinomas","volume":"92","author":"Kimura","year":"2001","journal-title":"Cancer"},{"key":"10.1016\/j.ucl.2019.09.006_bib25","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1002\/path.2207","article-title":"FGFR3 protein expression and its relationship to mutation status and prognostic variables in bladder cancer","volume":"213","author":"Tomlinson","year":"2007","journal-title":"J\u00a0Pathol"},{"key":"10.1016\/j.ucl.2019.09.006_bib26","doi-asserted-by":"crossref","first-page":"3664","DOI":"10.1200\/JCO.2005.05.1771","article-title":"Prospective study of FGFR3 mutations as a prognostic factor in nonmuscle invasive urothelial bladder carcinomas","volume":"24","author":"Hernandez","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"issue":"6","key":"10.1016\/j.ucl.2019.09.006_bib27","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/j.eururo.2017.05.032","article-title":"Next-generation sequencing of nonmuscle invasive bladder cancer reveals potential biomarkers and rational therapeutic targets","volume":"72","author":"Pietzak","year":"2017","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.ucl.2019.09.006_bib28","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.4238\/2014.February.20.12","article-title":"Clinical significance of fibroblast growth factor receptor-3 mutations in bladder cancer: a systemic review and meta-analysis","volume":"13","author":"Liu","year":"2014","journal-title":"Genet Mol Res"},{"issue":"12","key":"10.1016\/j.ucl.2019.09.006_bib29","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1038\/ng.2798","article-title":"Whole-genome and whole-exome sequencing of bladder cancer identifies alteration in genes involved in sister chromatid cohesion and segregation","volume":"45","author":"Guo","year":"2013","journal-title":"Nat Genet"},{"key":"10.1016\/j.ucl.2019.09.006_bib30","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1093\/hmg\/dds486","article-title":"Oncogenic FGFR3 gene fusions in bladder cancer","volume":"22","author":"Williams","year":"2013","journal-title":"Hum Mol Genet"},{"issue":"12","key":"10.1016\/j.ucl.2019.09.006_bib31","doi-asserted-by":"crossref","first-page":"3003","DOI":"10.1158\/1078-0432.CCR-16-2267","article-title":"A\u00a0phase II trial of dovitinib in BCG-unresponsive urothelial carcinoma with FGFR3 mutations or overexpression: Hoosier cancer research network trial HCRN 12-157","volume":"23","author":"Hahn","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ucl.2019.09.006_bib32","author":"Siefker-Radtke"},{"issue":"7","key":"10.1016\/j.ucl.2019.09.006_bib33","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1158\/2159-8290.CD-18-0229","article-title":"Efficacy of BGJ398, a fibroblast growth factor receptor 1-3 inhibitor, in patients with previously treated advanced urothelial carcinoma with FGFR3 alterations","volume":"8","author":"Pal","year":"2018","journal-title":"Cancer Discov"},{"issue":"45","key":"10.1016\/j.ucl.2019.09.006_bib34","doi-asserted-by":"crossref","first-page":"6469","DOI":"10.1038\/sj.onc.1210477","article-title":"The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis","volume":"26","author":"Moasser","year":"2007","journal-title":"Oncogene"},{"key":"10.1016\/j.ucl.2019.09.006_bib35","doi-asserted-by":"crossref","first-page":"42713","DOI":"10.1038\/srep42713","article-title":"Her2 alterations in muscle-invasive bladder cancer: Patient selection beyond protein expression for targeted therapy","volume":"7","author":"Kiss","year":"2017","journal-title":"Sci Rep"},{"issue":"2","key":"10.1016\/j.ucl.2019.09.006_bib36","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1136\/jclinpath-2012-200944","article-title":"Her2 amplification distinguishes a subset of non-muscle invasive bladder cancers with a high risk of progression","volume":"66","author":"Chen","year":"2013","journal-title":"J\u00a0Clin Pathol"},{"key":"10.1016\/j.ucl.2019.09.006_bib37","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1159\/000453670","article-title":"ERBB2 expression as potential risk-stratification for early cystectomy in patients with pT1 bladder cancer and concomitant carcinoma in situ","volume":"98","author":"Breyer","year":"2017","journal-title":"Urol Int"},{"key":"10.1016\/j.ucl.2019.09.006_bib38","doi-asserted-by":"crossref","first-page":"7401","DOI":"10.1158\/0008-5472.CAN-06-1182","article-title":"PIK3CA mutations are an early genetic alteration associated with FGFR3 mutations in superficial papillary bladder tumors","volume":"66","author":"Lopez-Knowles","year":"2006","journal-title":"Cancer Res"},{"issue":"46","key":"10.1016\/j.ucl.2019.09.006_bib39","doi-asserted-by":"crossref","first-page":"75176","DOI":"10.18632\/oncotarget.12661","article-title":"Genomic characterization of high risk non-muscle invasive bladder cancer","volume":"7","author":"Meeks","year":"2016","journal-title":"Oncotarget"},{"issue":"378","key":"10.1016\/j.ucl.2019.09.006_bib40","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aai8312","article-title":"Loss of tumor suppressor KDM6A amplifies PRC2-regulated transcriptional repression in bladder cancer and can be targeted through inhibition of EZH2","volume":"9","author":"Ler","year":"2017","journal-title":"Sci Transl Med"},{"issue":"4","key":"10.1016\/j.ucl.2019.09.006_bib41","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1158\/1541-7786.MCR-16-0003","article-title":"Understanding TERT promoter mutations: a common path to immortality","volume":"14","author":"Bell","year":"2017","journal-title":"Mol Cancer Res"},{"key":"10.1016\/j.ucl.2019.09.006_bib42","doi-asserted-by":"crossref","first-page":"17426","DOI":"10.1073\/pnas.1310522110","article-title":"TERT promoter mutations in bladder cancer affect patient survival and disease recurrence through modification by a common polymorphism","volume":"110","author":"Rachakonda","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ucl.2019.09.006_bib43","doi-asserted-by":"crossref","first-page":"7162","DOI":"10.1158\/0008-5472.CAN-13-2498","article-title":"TERT promoter mutations occur early in urothelial neoplasia and are biomarkers of early disease and disease recurrence in urine","volume":"73","author":"Kinde","year":"2013","journal-title":"Cancer Res"},{"key":"10.1016\/j.ucl.2019.09.006_bib44","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.eururo.2013.08.057","article-title":"Comprehensive mutation analysis of the TERT promoter in bladder cancer and detection of mutations in voided urine","volume":"65","author":"Hurst","year":"2014","journal-title":"Eur Urol"},{"issue":"17","key":"10.1016\/j.ucl.2019.09.006_bib45","doi-asserted-by":"crossref","first-page":"3219","DOI":"10.1002\/cncr.28147","article-title":"Recurrence of high-risk bladder cancer: a population-based analysis","volume":"119","author":"Chamie","year":"2013","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.ucl.2019.09.006_bib46","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.eururo.2018.09.002","article-title":"Genomic differences between \u201cprimary\u201d and \u201csecondary\u201d muscle-invasive bladder cancer as a basis for disparate outcomes to cisplatin-based neoadjuvant chemotherapy","volume":"75","author":"Pietzak","year":"2019","journal-title":"Eur Urol"},{"issue":"2","key":"10.1016\/j.ucl.2019.09.006_bib47","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.molmed.2012.10.009","article-title":"E2F1 apoptosis counterattacked: evil strikes back","volume":"19","author":"Putzer","year":"2013","journal-title":"Trends Mol Med"},{"issue":"23","key":"10.1016\/j.ucl.2019.09.006_bib48","doi-asserted-by":"crossref","first-page":"5391","DOI":"10.1158\/1078-0432.CCR-14-2680","article-title":"Activation of EZH2 and SUZ12 regulated by E2F1 predicts disease progression and aggressive characteristics of bladder cancer","volume":"21","author":"Lee","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.ucl.2019.09.006_bib49","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/S1535-6108(02)00102-2","article-title":"The RB and p53 pathways in cancer","volume":"2","author":"Sherr","year":"2002","journal-title":"Cancer Cell"},{"issue":"3","key":"10.1016\/j.ucl.2019.09.006_bib50","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/s00428-014-1699-y","article-title":"Tumor evolution and progression in multifocal and paired non-invasive\/invasive urothelial carcinoma","volume":"466","author":"Warrick","year":"2015","journal-title":"Virchows Arch"},{"key":"10.1016\/j.ucl.2019.09.006_bib51","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/j.eururo.2017.10.003","article-title":"Predicting response to intravesical bacillus calmette-guerin immunotherapy: are we there yet? A systemic review","volume":"73","author":"Kamat","year":"2018","journal-title":"Eur Urol"},{"issue":"5","key":"10.1016\/j.ucl.2019.09.006_bib52","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1016\/j.eururo.2007.10.006","article-title":"Prognostic factors in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guerin: multivariate analysis of data from four randomized CUETO trials","volume":"53","author":"Fernandez-Gomez","year":"2008","journal-title":"Eur Urol"},{"key":"10.1016\/j.ucl.2019.09.006_bib53","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.3389\/fimmu.2017.01679","article-title":"Neoantigens generated by individual mutations and their role in cancer immunity and immunotherapy","volume":"8","author":"Efremova","year":"2017","journal-title":"Front Immunol"},{"key":"10.1016\/j.ucl.2019.09.006_bib54","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1126\/science.aaa1348","article-title":"Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer","volume":"348","author":"Rizvi","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.ucl.2019.09.006_bib55","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1126\/science.aad0095","article-title":"Genomic correlates of response to CTLA-4 blockade in metastatic melanoma","volume":"350","author":"Van Allen","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.ucl.2019.09.006_bib56","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","article-title":"PD-1 blockade in tumors with mismatch-repair deficiency","volume":"372","author":"Le","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.ucl.2019.09.006_bib57","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/s41588-018-0312-8","article-title":"Tumor mutational load predicts survival after immunotherapy across multiple cancer types","volume":"51","author":"Samstein","year":"2019","journal-title":"Nat Genet"},{"key":"10.1016\/j.ucl.2019.09.006_bib58","article-title":"Pembrolizumab as neoadjuvant therapy before radical cystectomy in patients with muscle invasive urothelial bladder carcinoma (PURE-01): an open-label, single-arm, phase II study","author":"Necchi","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"issue":"12","key":"10.1016\/j.ucl.2019.09.006_bib59","doi-asserted-by":"crossref","first-page":"4104","DOI":"10.1245\/s10434-015-4431-5","article-title":"Genetic variations in glutathione pathway genes predict cancer recurrence in patients treated with transurethral resection and bacillus calmette-guerin instillation for non-muscle invasive bladder cancer","volume":"22","author":"Ke","year":"2015","journal-title":"Ann Surg Oncol"},{"issue":"5","key":"10.1016\/j.ucl.2019.09.006_bib60","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1111\/bju.12844","article-title":"The role of functional polymorphisms in immune response genes as biomarkers of bacille Calmette-Gu\u00e9rin (BCG) immunotherapy outcome in bladder cancer: establishment of a predictive profile in a Southern Europe population","volume":"116","author":"Lima","year":"2015","journal-title":"BJU Int"},{"issue":"7","key":"10.1016\/j.ucl.2019.09.006_bib61","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1158\/1078-0432.CCR-09-3323","article-title":"Gene signatures for the prediction of bacillus calmette-guerin immunotherapy in primary pT1 bladder cancers","volume":"16","author":"Kim","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ucl.2019.09.006_bib62","doi-asserted-by":"crossref","first-page":"S744","DOI":"10.21037\/tcr.2017.06.48","article-title":"The role of the tumor microenvironment in bladder cancer development and progression","volume":"6","author":"Kang","year":"2017","journal-title":"Transl Cancer Res"},{"issue":"10","key":"10.1016\/j.ucl.2019.09.006_bib63","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.3390\/ijms18102186","article-title":"Regulatory T cells and tumor-associated macrophages in the tumor microenvironment in non-muscle invasive bladder cancer treated with intravesical bacille Calmette-Gu\u00e9rin: a long-term follow-up study of a Japanese cohort","volume":"18","author":"Miyake","year":"2017","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10.1016\/j.ucl.2019.09.006_bib64","doi-asserted-by":"crossref","first-page":"e23","DOI":"10.1016\/j.urolonc.2013.06.008","article-title":"Predicting response to bacillus Calmette-Guerin (BCG) in patients with carcinoma in situ of the bladder","volume":"32","author":"Nunez-Nateras","year":"2014","journal-title":"Urol Oncol"},{"key":"10.1016\/j.ucl.2019.09.006_bib65","first-page":"2129","article-title":"Urinary Interleukin-8 and 18 predict the response of superficial bladder cancer to intravesical therapy with bacillus Calmette-Guerin","volume":"164","author":"Thalmann","year":"2000","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.ucl.2019.09.006_bib66","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1111\/j.1442-2042.2007.01696.x","article-title":"Intravesical instillation therapy with bacillus Calmette-Guerin for superficial bladder cancer: study of the mechanism of bacillus Calmette-Guerin immunotherapy","volume":"14","author":"Shintani","year":"2007","journal-title":"Int J Urol"},{"key":"10.1016\/j.ucl.2019.09.006_bib67","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s00262-016-1945-z","article-title":"Intratumoral Th2 predisposition combines with an increased Th1 functional phenotype in clinical response to intravesical BCG in bladder cancer","volume":"66","author":"Pichler","year":"2017","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.ucl.2019.09.006_bib68","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1046\/j.1365-2249.2003.02071.x","article-title":"Interleukin 10 induced augmentation of delayed-type hypersensitivity (DTH) enhances Mycobacterium bovis bacillus Calmette-Guerin (BCG) mediated antitumour activity","volume":"131","author":"Nadler","year":"2003","journal-title":"Clin Exp Immunol"},{"issue":"2","key":"10.1016\/j.ucl.2019.09.006_bib69","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.eururo.2015.06.023","article-title":"Cytokine panel for response to intravesical therapy (CyPRIT) nomogram of changes in urinary cytokine levels predicts patient response to bacillus Calmette-Guerin","volume":"69","author":"Kamat","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.ucl.2019.09.006_bib70","doi-asserted-by":"crossref","first-page":"39916","DOI":"10.18632\/oncotarget.9537","article-title":"Tumor-infiltrating immune cell subpopulations influence the oncologic outcome after intravesical bacillus Calmette-Guerin therapy in bladder cancer","volume":"7","author":"Pichler","year":"2016","journal-title":"Oncotarget"},{"issue":"5","key":"10.1016\/j.ucl.2019.09.006_bib71","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.eururo.2018.06.045","article-title":"Conventional and PD-L1-expressing regulatory T cells are enriched during BCG therapy and may limit its efficacy","volume":"74","author":"Chevalier","year":"2018","journal-title":"Eur Urol"},{"issue":"4","key":"10.1016\/j.ucl.2019.09.006_bib72","first-page":"481","article-title":"Manufacturing and the market: Rationalizing the shortage of bacillus Calmette-Gu\u00e9rin","volume":"4","author":"Bandari","year":"2018","journal-title":"Eur Urol"},{"issue":"4","key":"10.1016\/j.ucl.2019.09.006_bib73","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.eururo.2014.02.061","article-title":"Bacillus Calmette-Gu\u00e9rin strain differences have an impact on clinical outcome in bladder cancer immunotherapy","volume":"66","author":"Rentsch","year":"2014","journal-title":"Eur Urol"},{"issue":"8","key":"10.1016\/j.ucl.2019.09.006_bib74","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1002\/cncr.22588","article-title":"PD-L1 (B7-H1) expression by urothelial carcinoma of the bladder and BCG-induced gramulomata","volume":"109","author":"Inman","year":"2007","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.ucl.2019.09.006_bib75","doi-asserted-by":"crossref","first-page":"3503","DOI":"10.1038\/s41467-018-05992-x","article-title":"EMT- and stroma-related gene expression and resistance to PD-1 blockade in urothelial cancer","volume":"9","author":"Wang","year":"2018","journal-title":"Nat Commun"},{"issue":"10122","key":"10.1016\/j.ucl.2019.09.006_bib76","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/S0140-6736(17)33297-X","article-title":"Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicenter, open-label, phase 3 randomised controlled trial","volume":"391","author":"Powles","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.ucl.2019.09.006_bib77","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1056\/NEJMoa1613683","article-title":"Pembrolizumab as second-line therapy for advanced urothelial carcinoma","volume":"376","author":"Bellmunt","year":"2017","journal-title":"N\u00a0Engl J Med"}],"container-title":["Urologic Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0094014319300849?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0094014319300849?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T15:33:17Z","timestamp":1777476797000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0094014319300849"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":77,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["S0094014319300849"],"URL":"https:\/\/doi.org\/10.1016\/j.ucl.2019.09.006","relation":{},"ISSN":["0094-0143"],"issn-type":[{"value":"0094-0143","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Genomic and Therapeutic Landscape of Non-muscle-invasive Bladder Cancer","name":"articletitle","label":"Article Title"},{"value":"Urologic Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ucl.2019.09.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}